

September 27, 2022

Press release

General Incorporated Association EFPIA Japan  
(European Federation of Pharmaceutical Industries and Associations)

### EFPIA Japan Announces Winners for Fifth “PASE AWARD”, Patient Organization Support Program

TOKYO – 16 September 2022 – General Incorporated Association EFPIA Japan (European Federation of Pharmaceutical Industries and Associations) announced today winners for its Fifth PASE AWARD, selecting patient groups that particularly contribute to the evolution of Japan’s patient advocacy and offering grants totalling 1.10 million yen. This year’s theme is “Activities led by patient organizations for realization of patients’ better medical treatment and lives under the New Normal”, and EFPIA Japan started to call for entries from patient organizations in May and received applications from a total of 11 patient organizations by July 8. This year the “Grand Award” has been given to two groups, and the “Honor Award” has been given to three groups as below.

#### Fifth PASE AWARD winner organizations

Award	Award winning organization	Overview of application / proposal	Grant (JPY)
Grand Award	Certified Non-profit Organization KIBOUNOKAI	Creation of an educational booklet on gastric cancer	500,000
Honor Award	Specified Non-profit Corporation Cancer Forum Yamanashi	Internet Radio (I.R.)" to create a mechanism to receive and empathize with thoughts and feelings of patients and their families	150,000
Honor Award	General Incorporated Association Tekuteku Peer Net	Creation of a booklet on how to cope with disease and child rearing under new normal	150,000
Honor Award	Non-profit Organization Decoboco Life Design	Case studies on communication gap between people with developmental disabilities and their surroundings	150,000
Honor Award	Specified Non-profit Corporation Head and Neck Cancer Patient Support Network	Survey in patients and symposiums for both patients and healthcare professionals in collaboration with other head and neck cancer patient associations	150,000

EFPIA Japan Chair Takahiko Iwaya said, "I would like to thank all the patient organizations that applied for the Fifth PASE AWARD. It has been more than two years since the outbreak of COVID-19, and patient groups continue to make progress despite many restrictions associated with the pandemic. All the proposals received this time were very meaningful especially in these difficult times, and the selection on the Grand Award was extremely difficult. EFPIA Japan will continue to support the activities of these patient groups ultimately to ensure that patients in Japan have access to the latest medical care."

### **About the EFPIA Japan Patient Organization Support Program “PASE”**

“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program established in 2017 with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE was conceived to further encourage patient group activities in Japan, and to support the healthcare environment surrounding patients to evolve, so that it better reflects patients’ voices and patient needs. As part of PASE, EFPIA Japan decided to conduct the PASE AWARDS, in which grants of 1.10 million yen this year will be awarded to organizations that contribute to the evolution of patient advocacy (activities to protect patient rights).

### **About the Fifth “PASE AWARD”**

More than two years have passed since the outbreak of the COVID-19 pandemic. This impacts our lives and forces us to change our lifestyles in many ways. In such a situation, patient groups and individual patients have come to be required to adapt to new modes of lives, known as the “New Normal”. The fifth PASE AWARD this year called for activity plans of patient organizations to empower patients to have appropriate diagnosis, treatment and disease control while adapting to new lifestyles and preventing COVID-19 as well as activity plans to achieve healthcare policies that reflect patient voices under the New Normal. The draft plans were reviewed and selection was based on four evaluation criteria: “Having a clear purpose as a patient group and clear goals with KPIs”, “Showing concrete deliverables for achieving purpose in past activities”, “Having a specific implementation plan of activity for using grants (including how to use grants)”, “Being able to cooperate in disseminating the results of activities using grants (Allowing for posting on the EFPIA Japan website, notification and reporting on their own website)”. The organization that won the Grand Award will be offered a grant of 500,000 yen and be invited to attend the presentation ceremony on October 6, 2021. The four groups that won the Honor Award will be offered a grant of 150,000 yen. If you wish to participate in the Fifth PASE Award ceremony, please refer to the invitation letter, “EFPIA Day 2022 Special Press Conference,” issued on September 15.

### **The Fifth PASE Final Selection Committee Members**

- Mr. Takeo Nakayama (Kyoto University Faculty of Medicine, Professor of Health Informatics)
- Mr. Takahiko Iwaya, EFPIA Japan Chair (Sanofi K.K.)
- Mr. Leo Lee, EFPIA Japan Vice Chair (Novartis Co., Ltd.)
- Mr. Paul Lirette, EFPIA Japan Board Member (GlaxoSmithKline K.K.)
- Mr. Kana Matsumura, EFPIA Japan Governance and Legal Committee Chair (Nippon Boehringer Ingelheim Co., Ltd.)

### **About EFPIA Japan**

Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceutical companies operating in Japan. In 2021, combined sales from the member companies accounted for roughly 26% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.



European Federation of Pharmaceutical  
Industries and Associations

### **About the European Federation of Pharmaceutical Industries and Associations (EFPIA)**

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 38 leading pharmaceutical companies and a growing number of small and medium-sized enterprises (SMEs), EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Details can be found below.

<http://efpia.jp/> (EFPIA Japan)

<http://www.efpia.eu> (EFPIA)

### **Inquires to :**

Hitoshi Fujita  
EFPIA Japan Public Relations Committee, person in  
charge of PASE  
Novartis Pharma K.K.  
Toranomon Hills Mori tower  
1-23-1 Toranomon, Minato-ku, Tokyo 105-6333  
TEL: 090-9837-4326  
E-mail: hitoshi.fujita@novartis.com

Naomi Sakai  
EFPIA Japan Patient Committee, person in charge of  
PASE  
Nippon Boehringer Ingelheim Co., Ltd.  
ThinkPark Tower  
2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017  
TEL: 03-6417-2489  
E-mail: naomi.sakai@boehringer-ingelheim.com

---

EFPIA Japan

Tokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan